@article{cf2069e5a5694263836fef7dbb6223ca,
title = "A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing",
abstract = "Background: For human papillomavirus (HPV) DNA detection, specimen collection and transportation using a dry swab without transport medium has advantages, in various situations, over liquid media. Objective: In this pilot study we evaluated whether a dry cervical sample taken with a flocked swab (dry sample) is a valid alternative for HPV DNA testing compared with the standard practice of a wet sample taken with a cyto-broom placed directly into liquid media (wet sample). Study design: Women attending the dysplasia clinic at the Royal Women's Hospital, Melbourne Australia between November 2013 and February 2014 were enrolled. During colposcopic examination, a practitioner collected wet and dry cervical samples, with the order of collection randomised. In the laboratory both samples were left for a week before being tested for 14 high-risk HPV types using the Roche Cobas 4800 test. Results: Overall, 209 had valid HPV results from both samples. The observed agreement for HPV detection between wet and dry samples was 92.8% and kappa was 0.85 (95% confidence interval (95% CI): 0.78-0.92). There was no statistical difference in the percent HPV positive for each sample (p=0.30). HPV testing of the dry sample had an 88.5% (95% CI: 79.9-94.3%) sensitivity for HPV detected using the wet specimen. For the HPV results categorized hierarchically, there was 92.8% overall agreement and a kappa of 0.87 (95% CI=0.80-0.93) for the paired results. Conclusion: Using dry flocked swabs to collect cervical cells is a valid alternative to collecting wet samples for HPV DNA testing using a PCR based test.",
keywords = "Cervical sample, Dry swab, HPV testing, Randomised",
author = "Farhana Sultana and Gertig, {Dorota M.} and Wrede, {C. David} and English, {Dallas R.} and Simpson, {Julie A.} and Drennan, {Kelly T.} and Brotherton, {Julia M.L.} and Gillian Phillips and Stella Heley and Castle, {Philip E.} and Marion Saville",
note = "Funding Information: Competing interests: M.S. is a co-Principal Investigator on the Compass Trial. D.G., P.C. and J.B. are Chief Investigators on the Compass Trial. GP and SH are Associate Investigators. Compass in an investigator initiated trial that has received partial funding support from Roche Molecular Systems and Ventana Inc, USA. Dr Castle has received commercial HPV tests for research at a reduced or no cost from Roche, Qiagen, Norchip, Arbor Vita Corporation, BD, and mtm. He has been compensated financially as a member of a Merck Data and Safety Monitoring Board for HPV vaccines. Dr Castle has been paid as consultant for BD, Gen-Probe/Hologic, Roche, Cepheid, ClearPath, Guided Therapeutics, Teva Pharmaceutics, Genticel, Inovio, and GE Healthcare. Dr Castle has received honoraria as a speaker for Roche and Cepheid. All authors have no other potential or actual conflict of interest to declare. Funding Information: F.S. is supported by the Endeavour Postgraduate Scholarships and Fellowships sponsored by the Australian Government, Department of Education and Training . We thank Barbara McBride, Nurse Coordinator, Amy Cooper, Clinical Nurse Specialist and all the other staff at the Dysplasia clinic for their support during the period of data collection. We also thank the VCS Pathology staff for processing and testing the samples. We also acknowledge all participating women. Publisher Copyright: {\textcopyright} 2015 Elsevier B.V.",
year = "2015",
month = aug,
day = "1",
doi = "10.1016/j.jcv.2015.06.080",
language = "English (US)",
volume = "69",
pages = "210--213",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
}